| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TMO | Common Stock | Sale | -$641K | -1.16K | -1.96% | $552.72 | 58K | Feb 7, 2024 | By Floral Park Associates, Inc. | F1, F2 |
| transaction | TMO | Common Stock | Sale | -$332K | -600 | -1.03% | $553.83 | 57.4K | Feb 7, 2024 | By Floral Park Associates, Inc. | F1, F3 |
| transaction | TMO | Common Stock | Sale | -$1.73M | -3.13K | -5.45% | $554.81 | 54.3K | Feb 7, 2024 | By Floral Park Associates, Inc. | F1, F4 |
| transaction | TMO | Common Stock | Sale | -$1.8M | -3.23K | -5.95% | $555.87 | 51K | Feb 7, 2024 | By Floral Park Associates, Inc. | F1, F5 |
| transaction | TMO | Common Stock | Sale | -$501K | -900 | -1.76% | $556.82 | 50.1K | Feb 7, 2024 | By Floral Park Associates, Inc. | F1, F6 |
| transaction | TMO | Common Stock | Sale | -$112K | -200 | -0.4% | $557.74 | 49.9K | Feb 7, 2024 | By Floral Park Associates, Inc. | F1, F7 |
| transaction | TMO | Common Stock | Sale | -$224K | -400 | -0.8% | $561.03 | 49.5K | Feb 7, 2024 | By Floral Park Associates, Inc. | F1, F8 |
| transaction | TMO | Common Stock | Sale | -$215K | -382 | -0.77% | $562.38 | 49.2K | Feb 7, 2024 | By Floral Park Associates, Inc. | F1, F9 |
| holding | TMO | Common Stock | 131K | Feb 7, 2024 | Direct | ||||||
| holding | TMO | Common Stock | 11.3K | Feb 7, 2024 | By Alison Casper 2020 Irrevocable Trust | F10 | |||||
| holding | TMO | Common Stock | 5K | Feb 7, 2024 | By MNC 2020 Irrevocable Trust | F11 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, entered into on March 3, 2023. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $552.16 to $553.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8) and (9) to this Form 4. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $553.24 to $554.14, inclusive. |
| F4 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $554.25 to $555.20, inclusive. |
| F5 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $555.33 to $556.26, inclusive. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $556.55 to $557.13, inclusive. |
| F7 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $557.58 to $557.90, inclusive. |
| F8 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $560.83 to $561.63, inclusive. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $561.92 to $562.64, inclusive. |
| F10 | The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. |
| F11 | The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. |